1 |
Distefano M, Ferlini C, De Vincenzo R, et al (2001). Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells. Oncol Res, 12, 335-59.
DOI
|
2 |
Hahnvajanawong C, Bhudisawadi V, Namwat N, et al (2011). Comparative in vitro cytotoxicity of the generic and reference products of gemcitabine on various cancer cell lines. Srinagarind Med J, 26, 1-8.
|
3 |
Huang P, Chubb S, Hertel L, et al (1991). Action of 2_,2_-diflurodeoxycytidine on DNA synthesis. Cancer Res, 51, 6110-7.
|
4 |
Heinemann V, Xu YZ, Chubb S, et al (1990). Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2_,2_-difluorodeoxycytidine. Mol Pharmacol, 38, 567-72.
|
5 |
Heinemann V, Hertel LW, Grindey GB, et al (1988). Comparison of the cellular pharmacokinetics and toxicity of 2_,2_-difluorodeoxycytidine and 1-beta-d-arabinofuranosyl cytosine. Cancer Res, 48, 4024-31.
|
6 |
Lorusso D, Di Stefano A, Fanfani F, et al (2006). Role of gemcitabine in ovarian cancer treatment. Ann Oncol, 17, 188-94.
DOI
|
7 |
Mutch DG, Orlando M, Goss T, et al (2007). Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol, 25, 2811-8.
DOI
ScienceOn
|
8 |
Mackey JR, Mani RS, Selner M, et al (1998). Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res, 58, 4349-57.
|
9 |
Miller AB, Hoogstraten B, Staquet M,et al (1981). Reporting results of cancer treatment . Cancer, 47, 207-14.
DOI
ScienceOn
|
10 |
Ojeda Gonzalez B, Gonzalez Martin A, Bover Barcelo I, et al (2008). A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial. Am J Clin Oncol, 31, 481-7.
DOI
|
11 |
Peters GJ, Bergman AM, Ruiz van Haperen VW, et al (1995). Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol, 22, 72-9.
|
12 |
Van Moorsel CJ, Peters GJ, Pinedo HM (1997). Gemcitabine: future prospects of single-agent and combination studies. Oncologist, 2, 127-34.
|
13 |
Rustin GJ, Vergote I, Eisenhauer E, et al (2011). Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer, 21, 419-23.
DOI
ScienceOn
|
14 |
Ruiz van Haperen VW, Veerman G, Boven E, et al (1994). Schedule dependence of sensitivity to 29,29-difluorodeoxycytidine- (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol, 48, 1327-39.
DOI
|
15 |
Ruiz van Haperen VW, Veerman G, Vermorken JB, et al (1993). 2',2'-Diflurodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem Pharmacol , 46, 762-6.
DOI
|
16 |
Watanabe Y, Koike E, Nakai H, et al (2008). Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer. Int J Clin Oncol, 13, 345-8.
DOI
ScienceOn
|